This relationship between CES values and patient survival was also evident in ER− breast cancers (mainly basal-like and HER2+ subtypes) (Fig. 7g; Supplementary Fig. 32), as well as in lung SCC or stage II NSCLC patients that are enriched for high CES tumours (Fig. 5c,d; Supplementary Figs 16 and 17). This evidence concerns the gene ERBB2 and neoplasm.